RecruitingAcute Spinal Cord Injury
Spinal Cord Injury Neuroprotection With Glyburide
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
Sponsor: Francis Farhadi
You may qualify if…
- ✓ No life threatening injuries resulting from the traumatic accident
- ✓ No evidence of sepsis
- ✓ Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission.
- ✓ Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12
You may not qualify if…
- ✕ Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours
- ✕ Acute SCI with ASIA Impairment Scale grade D or E
- ✕ Currently involved in another non-observational SCI research study or receiving another investigational drug
- ✕ History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components
- ✕ Any condition likely to result in the patient's death within the next 12 months
- ✕ Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \< 30 mL/min/1.73 m2
- ✕ Known severe liver disease, or ALT \> 3 times upper limit of normal or bilirubin
- ✕ Blood glucose \<55 mg/dL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia
Where it's recruiting
Kentucky
Lexington
Source: ClinicalTrials.gov · NCT05426681 · last updated 2026-02-13